Edwards Lifesciences price target raised to $89 from $85 at RBC Capital

RBC Capital raised the firm’s price target on Edwards Lifesciences (EW) to $89 from $85 and keeps an Outperform rating on the shares. Edwards delivered sales and EPS upside and raised the low end of 2025 revenue guidance, noting confidence at the high end of EPS, the analyst tells investors in a research note. The current sentiment and valuation support upside, the firm says.